NASDAQ:BCLIBrainstorm Cell Therapeutics Stock Price, Forecast & News

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has decreased by 2.5% and is now trading at $6.51. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.09. View Brainstorm Cell Therapeutics' earnings history.

1 Wall Street analysts have issued twelve-month price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View analysts' price targets for Brainstorm Cell Therapeutics.

Headlines about BCLI stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutBrainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,290,000 shares, an increase of 22.5% from the April 15th total of 1,870,000 shares. Based on an average daily trading volume, of 754,300 shares, the days-to-cover ratio is presently 3.0 days. Approximately 10.8% of the shares of the stock are short sold. View Brainstorm Cell Therapeutics' Current Options Chain.

Some companies that are related to Brainstorm Cell Therapeutics include Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Prevail Therapeutics (PRVL), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), MeiraGTx (MGTX), Harpoon Therapeutics (HARP), Innate Pharma (IPHYF), Scholar Rock (SRRK) and Nantkwest (NK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Protalix Biotherapeutics (PLX), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), IsoRay (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.46%), Raymond James & Associates (0.77%), Geode Capital Management LLC (0.58%), EAM Investors LLC (0.44%), Phoenix Holdings Ltd. (0.40%) and WINTON GROUP Ltd (0.26%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View institutional ownership trends for Brainstorm Cell Therapeutics.

BCLI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., EAM Investors LLC, Phoenix Holdings Ltd., Raymond James & Associates, JPMorgan Chase & Co., Abner Herrman & Brock LLC, Geode Capital Management LLC, and Steward Partners Investment Advisory LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include June Sherie Almenoff, Preetam Shah, and Ralph Dr Kern. View insider buying and selling activity for Brainstorm Cell Therapeutics.

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BCLI stock can currently be purchased for approximately $6.51.

Brainstorm Cell Therapeutics has a market capitalization of $191.66 million. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.

The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]